secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2026-09-29T13:15:22+00:00
Accession:  0001104659-26-111665
Event type: regulatory
Sentiment:  positive
Materiality: 0.45
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Liminatus Pharma regains Nasdaq minimum bid price compliance after 1-for-50 reverse split
--------------------------------------------------------------------------------

- Nasdaq notice dated Sept 24, 2026: closing bid price was above $1.00 for 13 consecutive trading days from Aug 21 to Sept 9, 2026; the matter is now closed.
- Company effected a 1-for-50 reverse stock split at the close of trading on Aug 20, 2026 to cure the bid price deficiency.
- Original Jan 15, 2026 notice: bid below $1.00 for 30 consecutive business days, failing Nasdaq Listing Rule 5450(a)(1) for the Global Market.
- Nasdaq Hearings Panel transferred the company to the Nasdaq Capital Market effective Aug 4, 2026 and set a Sept 3, 2026 deadline under Rule 5550(a)(2).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/0001104659-26-111665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/tm2626488d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-111665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer